IGF-1R as an anti-cancer target--trials and tribulations.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical trial observations and mechanisms without systematic review methodology
PubMed 23601239 · doi:10.5732/cjc.012.10263
What was done
This narrative review summarizes clinical trial findings and mechanisms for over 10 IGF and IGF-1R inhibitors categorized into three classes: monoclonal antibodies against IGF-1R, monoclonal antibodies against IGF-1/IGF-2 ligands, and IGF-1R tyrosine kinase inhibitors.
What was found
The abstract reports no numerical data. It notes that sustained responses were observed in a small number of patients with select cancers (Ewing sarcoma and thymoma), while large trials in major adult cancers (non-small cell lung cancer, breast cancer, and pancreatic cancer) failed to demonstrate overall clinical benefit due to pathway complexity, parallel survival signaling, and a lack of predictive patient selection markers.
Why it matters
It outlines the clinical limitations of unselected IGF-1R targeting in solid tumors and underscores the necessity of predictive biomarkers and rational combination regimens for future drug development.
Limits
As a narrative review, the abstract reports no specific sample sizes, trial counts, effect sizes, or systematic search criteria. Findings are qualitative and aggregate results across heterogeneous tumor types and drug classes.
Cited by
- supports Multiple clinical trials evaluating IGF-1 pathway inhibitors as cancer therapies failed.